IDT launches new RNA sequencing based solid tumor panel assay for cancer research

Google+ Pinterest LinkedIn Tumblr +


New panel leverages Anchored Multiplex PCR (AMP™) chemistry and Archer Analysis to detect fusions, splice variants and more, enabling downstream application of precision medicine

Integrated DNA Technologies (IDT), a global genomics solutions provider, is supporting research labs worldwide with a new solution to optimize operational efficiency and the identification of solid cancer tumors. The just-launched IDT Archer FUSIONPlex Core Solid Tumor Panel is a first-line cancer research testing solution that has been expanded and optimized for additional single nucleotide variant (SNV) and indel coverage to streamline fusion detection and variant calling through a single assay. The new RNA-based sequencing offering for solid tumors uses a single RNA/TNA input sample and provides a scalable, easy-to-use solution that offers time, resource and cost savings for researchers.

“With the race to provide accurate and timely oncology data, labs are on a continuous pursuit to do more with less—less effort, less time and less expense,” said Verity Johnson, VP of Archer Product at IDT. “The Archer FUSIONPlex Core Solid Tumor Panel paired with Archer Analysis responds to the challenges labs are facing worldwide and delivers a thoughtfully curated solution that enables researchers to more rapidly build comprehensive biomarker profiles from a single, limited input sample. As discoveries lead to more scientific advances, time is of the essence, and IDT is proud to provide cutting-edge solutions that can help accelerate the path toward cancer breakthroughs.”

As cancer is a complex disease to study with multiple important biomarkers, a comprehensive discovery method is becoming increasingly critical to researchers. The Archer FUSIONPlex Core Solid Tumor Panel provides a new approach to researchers looking for an alternative to current methods, which require running a minimum of two assays—one DNA- and one RNA-based—to address comprehensive profiling research. The Archer Analysis software platform offers purpose-built bioinformatics with an easy-to-use interface for all Archer products. The redesigned RNA variant detection pipeline on Archer Analysis v7.1 leverages an updated small variant detection algorithm and provides more intuitive genomic visualizations.

The FUSIONPlex Core Solid Tumor Panel is a balanced pool of gene-specific primer (GSP) oligonucleotides targeting 56 genes. Designed with simplicity in mind, AMP-based library preparation for Archer NGS research assays can be implemented in 1.5 days with minimal hands-on time. For more information and to place an order, visit here.

SourceBusinessWire

Share.